Literature DB >> 11106103

Clinical features and etiology of hepatocellular carcinoma arising in patients with membranous obstruction of the inferior vena cava: in reference to hepatitis viral infection.

S Matsui1, T Ichida, M Watanabe, S Sugitani, T Suda, T Takahashi, H Asakura.   

Abstract

BACKGROUND AND AIMS: Budd-Chiari syndrome (BCS) comprises hepatic vein thrombosis and inferior vena cava (IVC) obstruction known as membranous obstruction of the IVC (MOVC). The latter is frequently complicated by hepatocellular carcinoma (HCC). The etiology of MOVC-associated HCC in relation to hepatitis viral infection is not known. In this study, we investigated the clinical features and etiology of HCC in MOVC.
METHODS: Membranous obstruction of IVC and HCC were diagnosed and studied by using imaging techniques. Sera from patients with MOVC, complicated by HCC, were examined for hepatitis viral antigens and antibodies (hepatitis B surface antigen (HBsAg), antibody to HBsAg (anti-HBs), antibody to hepatitis B core antigen (anti-HBc) and third generation antibody to hepatitis C virus (anti-HCV)) and for hepatitis viral nucleic acids (hepatitis B virus (HBV)-DNA, hepatitis C virus (HCV)-RNA, hepatitis G virus (HGV)-RNA and TT virus DNA).
RESULTS: We studied 12 patients with BCS who were seen between April 1968 and February 1999. All of them had MOVC. Hepatocellular carcinoma developed in three (25%) of them. There were no obvious differences in the clinical features and imaging findings concerning MOVC between patients with and without HCC. Hepatocellular carcinoma in these three patients showed no clear trend in clinical features and imaging findings. Of the hepatitis viral markers examined, HBsAg, anti-HBc and HBV-DNA were positive in only one of three patients with HCC and all of the viral markers were negative in the other two patients.
CONCLUSIONS: Chronic congestion in the liver, caused by an outflow block of hepatic veins and subsequent histopathologic change, must have led to HCC in two patients without any hepatitis viral markers. Patients with MOVC should be followed closely as a high-risk group for HCC.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11106103     DOI: 10.1046/j.1440-1746.2000.02303.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  9 in total

1.  Studies on Budd-chiari syndrome complicated with hepatocellular carcinoma: most patients without inferior vena cava obstruction.

Authors:  Xiaowei Dang; Luhao Li; Suxin Li; Yafei Wang; Hai Li; Shaokai Xu; Peiqin Xu
Journal:  Int J Clin Exp Med       Date:  2015-06-15

2.  Congenital malformations of the suprahepatic inferior vena cava: an easily overlooked etiology of chronic liver disease with tumor-like nodules.

Authors:  Giovanna Borghi-Scoazec; Pierre Rocca-Zanella; Pierre-Jean Valette; Didier Revel; Olivier Boillot; Christian Trepo; Jean-Yves Scoazec
Journal:  Dig Dis Sci       Date:  2006-02       Impact factor: 3.199

Review 3.  Hepato-cardiac disorders.

Authors:  Yasser Mahrous Fouad; Reem Yehia
Journal:  World J Hepatol       Date:  2014-01-27

Review 4.  Budd-Chiari syndrome/hepatic venous outflow tract obstruction.

Authors:  Dominique-Charles Valla
Journal:  Hepatol Int       Date:  2017-07-06       Impact factor: 6.047

5.  Etiology of non-B non-C hepatocellular carcinoma in the eastern district of Tokyo.

Authors:  Hiroshi Abe; Kai Yoshizawa; Takuya Kitahara; Ryoichi Aizawa; Mika Matsuoka; Yoshio Aizawa
Journal:  J Gastroenterol       Date:  2008-12-24       Impact factor: 7.527

6.  Hepatocellular carcinoma in Budd-Chiari syndrome: a single center experience with long-term follow-up in South Korea.

Authors:  Hana Park; Jin Young Yoon; Kyeong Hye Park; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han; Chae Yoon Chon; Jun Yong Park
Journal:  World J Gastroenterol       Date:  2012-04-28       Impact factor: 5.742

7.  Budd-Chiari syndrome: two cases with different courses.

Authors:  Shinjiro Inomata; Yasuaki Takeyama; Takashi Tanaka; Shu-Ichi Ueda; Daisuke Morihara; Shinya Nishizawa; Teruo Matsumoto; Akira Anan; Hirokatsu Nishimura; Makoto Irie; Kaoru Iwata; Satoshi Shakado; Tetsuro Sohda; Hideyuki Higashihara; Masatoshi Okazaki; Shotaro Sakisaka
Journal:  Case Rep Gastroenterol       Date:  2008-08-15

8.  Rapidly progressing Budd-Chiari syndrome complicated by hepatocellular carcinoma.

Authors:  Jeong Won Jang; Seung Kew Yoon; Si Hyun Bae; Jong Young Choi; Kyu Won Chung; Hee Sik Sun
Journal:  Korean J Intern Med       Date:  2003-09       Impact factor: 2.884

9.  Combining angioplasty with percutaneous microwave ablation for treating primary Budd-Chiari syndrome associated with hepatocellular carcinoma in two patients: A case report.

Authors:  Qing-Qiao Zhang; Mao-Heng Zu; Hao Xu; Yu-Ming Gu; Wen-Liang Wang; Zhi-Kang Gao
Journal:  Oncol Lett       Date:  2013-06-20       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.